Clinical trials: Cancer Progression
Type 1 Diabetes Mellitus
Effect of CSII and CGM on Progression of Late Diabetic Complications
The purpose of the study is to investigate whether the combination of insulin pump therapy and continued glucose monitoring (CGM) is superior to multiple daily insulin injections to prevent progression of albuminuria in patients…
- Trial name
- NCT01454700
- Testing
- Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM), Multiple daily insulin injections (MDI)
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Steen Andersen
Breast Cancer
Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer
GEICAM/2012-07 is a study phase III, prospective, open, randomized, multicenter and national designed to assess patient preference for intravenous (IV) or subcutaneous (SC) of trastuzumab, and within the SC by the administration…
- Trial name
- ChangHER-SC (NCT01875367)
- Testing
- Trastuzumab Injectable Solution, Trastuzumab Injectable Product, Trastuzumab Injection
- Where
- 27 sites in Spain
- Volunteers
- 166 people
- Sponsor
- Spanish Breast Cancer Research Group
Alzheimer's Disease
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild…
- Trial name
- PrevenTRON (NCT07717411)
- Testing
- Trontinemab
- Where
- 34 sites in United States, Argentina and 5 more
- Volunteers
- 1,600 people
- Sponsor
- Hoffmann-La Roche
Age Related Macular Degeneration
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The overall objective of this two arm randomized clinical trial (RCT) is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device in AREDS2 improves detection…
- Trial name
- AREDS (NCT01103505)
- Testing
- ForeseeHome AMD Monitoring Device
- Where
- 38 sites in United States
- Volunteers
- 1,520 people
- Sponsor
- Notal Vision Ltd.
Lung Cancer, Psychological Stress
The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
This is the prospective, observational cohort study (STRESS-LUNG) to explore the associations of psychological stress with progression, efficacy of immune checkpoint inhibitors (ICIs) and prognosis of Lung Cancer.
- Conditions
- Lung Cancer, Psychological Stress, Immune Checkpoint Inhibitors, Cancer, Treatment-Related
- Trial name
- NCT05477979
- Testing
- Exposure: psychological stress status
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Second Xiangya Hospital of Central South University
Ovarian Cancer
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer
The primary objective of this study is to evaluate 12 weeks progression-free survival (PFS) rate of Palbociclib plus Letrozole in ER/PR positive endometrioid or high-grade serous ovarian cancer who have disease progression on…
- Trial name
- NCT03936270
- Testing
- Palbociclib 125mg, Letrozole 2.5mg
- Where
- 5 sites in Brazil
- Volunteers
- 43 people
- Sponsor
- Latin American Cooperative Oncology Group
Coronary Heart Disease
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors.
- Trial name
- NCT00655473
- Testing
- Dalcetrapib (RO4607381)
- Where
- 12 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Myeloid
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
It is often impossible to find therapeutic target in intermediate-risk AML, so it is very important to select appropriate chemotherapy protocol to eliminate minimal residual disease (MRD) in these AML patients.
- Trial name
- NCT03417427
- Testing
- Decitabine and Ara-C, Ara-C
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xuejie Jiang
Humoral Rejection in Kidney Transplantation
Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
Assessing the impact of J12 curative treatment with rituximab (375 mg / m² on J5) based on a composite "TREATMENT FAILURE"
- Trial name
- RITUX-ERAH (NCT01350882)
- Testing
- MabThera, Physiological serum : sodium chloride, sodium citrate
- Where
- 30 sites in France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Tours
Glioblastoma, IDH-Wildtype
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma.
- Trial name
- GABLE (NCT06319027)
- Testing
- Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Fluciclovine F18, Gadolinium-Chelate
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Bronchiectasis Adult, Radiomics
Multicenter Cohort Study on Predicting Bronchiectasis Progression, Complications, and Prognosis Using Multi-omics
Bronchiectasis is a heterogeneous condition with diverse etiologies and clinical manifestations. Its progression involves a vicious cycle of airway inflammation, recurrent infection, and structural damage, leading to persistent…
- Trial name
- NCT07263373
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Superficial Bladder Cancer t1a
Skipping BCG for T1a Urinary Bladder Tumor.
Bladder cancer is the most common malignancy involving theurinary system and the ninth most common malignancy worldwide .In Egypt, the urinary bladder cancer accounted for about 31% of the total incidence of cancers that…
- Trial name
- NCT04298073
- Volunteers
- 43 people
- Sponsor
- Assiut University
Dupuytren's Disease
Nodular Shrinking in Dupuytren Disease
Dupuytren disease (DD) is a common hand disorder with disabling finger contractures that may require surgery to restore function.
- Trial name
- Echo (NCT06321991)
- Testing
- Ultrasound measurement
- Where
- Belgium
- Volunteers
- 80 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Robot-Assisted Radical Prostatectomy Training, Prostatectomy
Comparing Two Training Methods for Learning Robot-Assisted Radical Prostatectomy
This randomized non-inferiority study evaluates whether a robot-assisted radical prostatectomy (RARP) training pathway incorporating the IMRA Surgical Prostatectomy Class V Hydrogel Model is as effective as the current standard…
- Trial name
- NCT07669974
- Testing
- IMRA-Enhanced Training Pathway, Standard Training Pathway
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Orsi Academy
Liver Cancer, Pembrolizumab
The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications.
Hepatocellular carcinoma (HCC) is one of the most significant cancers in our country. Since 2019, many first-line and second-line therapeutic agents for HCC have been introduced.
- Conditions
- Liver Cancer, Pembrolizumab, Atezolizumab, Lenvatinib
- Trial name
- NCT07233759
- Where
- Taiwan
- Volunteers
- 2,500 people
- Sponsor
- National Taiwan University Hospital
Glioma, Glioblastoma
Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms
This pilot study will assess feasibility and to obtain initial estimates of efficacy of Sleep Activity and Task Effectiveness (SAFTE) model, which can accurately estimate the impact of scheduling factors and sleep history on both…
- Trial name
- NCT03877861
- Testing
- Readiband Sleep Tracking
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Allina Health System
Epithelial Ovarian Cancer, Homologous Recombination Deficiency
HRD and Resistance to PAPPi in EOC Patients
The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in previous studies (NCT04190667…
- Conditions
- Epithelial Ovarian Cancer, Homologous Recombination Deficiency, Homologous Recombination Repair Gene Mutation, Poly(ADP-ribose) Polymerase Inhibitor
- Trial name
- NCT05310370
- Testing
- Testing of homologous recombination deficiency
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Lei Li
Malignant Gliomas
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months.
- Trial name
- NCT00463073
- Testing
- Cetuximab, Bevacizumab, Irinotecan
- Where
- 3 sites in Denmark
- Volunteers
- 32 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Advanced or Metastatic Non-small Cell Lung Cancer
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human…
- Trial name
- PALOMA-3 (NCT05388669)
- Testing
- Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous
- Where
- 187 sites in United States, Argentina and 18 more
- Volunteers
- 418 people
- Sponsor
- Janssen Research & Development, LLC
Squamous Cell Carcinoma of the Oropharynx
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
- Trial name
- NCT04398524
- Testing
- ISA101b
- Where
- 41 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- ISA Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.